Quốc gia: Úc
Ngôn ngữ: Tiếng Anh
Nguồn: Department of Health (Therapeutic Goods Administration)
lacosamide, Quantity: 150 mg
Alembic Pharmaceuticals Australia Pty Ltd
Tablet, film coated
Excipient Ingredients: magnesium stearate; crospovidone; hyprolose; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; iron oxide black; macrogol 400
Oral
14, 56
(S4) Prescription Only Medicine
Alembic Lacosamide (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.
Visual Identification: Salmon, oval, film-coated tablets debossed with "L425" on one side and plain on other side; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2021-05-11